āK
EDX Medical Group PLC announced on June 4, 2026, that Jason Christopher Holt, its non-executive chairman, resigned his directorship of European Cargo Limited (ECL) on September 5, 2025. ECL subsequently entered into administration on June 3, 2026, with no business relationship existing between EDX Medical Group PLC and ECL.
| Date | 4 Jun 2026 |
| Time | 16:04:41 |
| Category | Miscellaneous |
| ID | 0905H |
ā
June 4, 2026
("EDX Medical" or the "Company")
Rule 17 disclosure
CAMBRIDGE, UK: EDX Medical (TIDM: EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer and infectious diseases, provides the following update pursuant to Rule 17 and Schedule 2g of the AIM Rules.
Jason Christopher Holt, non-executive chairman of EDX Medical, was a director of European Cargo Limited (ECL) and resigned that directorship on September 5, 2025. ECL subsequently entered into administration on June 3, 2026. There is no business relationship between EDX Medical and ECL.
ENDS
For enquiries, please contact:
|
EDX Medical Group plc |
|
|
Dr Mike Hudson (Chief Executive Officer)
|
+44 (0)7812 345 301 |
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Stuart Andrews |
+44 (0) 20 7523 8318 |
|
Media House International |
|
|
Ramsay Smith
Gary McQueen |
+44 (0)7788 414856 + 44 (0)7834 694609
|
|
IFC Advisory (Investor Relations) |
|
|
Graham Herring Tim Metcalfe |
+44 (0) 203 934 6630 |
About EDX Medical Group plc
The EDX Medical Group plc is listed on the AIM market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.